Troglitazone ameliorates insulin resistance in a diabetic patient with Prader-Willi syndrome

Diabetes Research and Clinical Practice

Volumn 42, Issue 3, 1998, Pages 205-208

  Yamakita, Tetsuya ^a   Ishii, Tomofusa ^a   Mori, Tomoko ^a   Yoshioka, Katsunobu ^a   Sato, Toshihiko ^a   Tanaka, Shiro ^a   Kurimasa, Hiroko ^a   Fujita, Keinosuke ^a   Fujii, Satoru ^a  

^a OSAKA CITY GENERAL HOSPITAL   (Japan)

Author keywords

Insulin sensitivity; Prader Willi syndrome; Troglitazone

Indexed keywords

GLUCOSE; TROGLITAZONE;

ADOLESCENT; ARTICLE; CASE REPORT; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFECT; GENETIC DISORDER; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HUMAN; HYPOGONADISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; MENTAL DEFICIENCY; MORBID OBESITY; PRADER WILLI SYNDROME; WEIGHT GAIN;

ADOLESCENT; BLOOD GLUCOSE; CHROMANS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; OBESITY; PRADER-WILLI SYNDROME; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0032433323     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(98)00111-9     Document Type: Article

References (16)

1. Donaldson M.D.C., Chu C.E., Cooke A. et al. The Prader-Willi syndrome. Arch. Dis. Child. 70:1994;58-63. (Review).
2. Cassidy S. Prader-Willi syndrome. Curr. Probl. Pediatr. 14:1984;5-55.
3. Nozaki Y., Katoh K. Endocrinological abnormalities in Prader-Willi syndrome. Acta Pediatr. Jpn. 23:1981;301-306.
4. Reda B., William H.H., Harold C., Cathy M.T. Hyperlipidemia, insulin dependent diabetes mellitus and rapidly progressive diabetic retinopathy and nephropathy in Prader-Willi syndrome with Del(15)(q11.2q13). Am. J. Med. Genet. 71:1997;267-270.
5. Hall B.D., Smith D.W. Prader-Willi syndrome. A resume of 32 cases including an instance of affected first cousins, one of whom is of normal stature and intelligence. J. Pediatr. 81:1972;286-293.
6. Laurance B.M., Brito A, Wilkinson J. The Prader-Willi syndrome after the age of 15 years. Arch. Dis. Childhood. 56:1981;181.
7. Kousholt A.M., Beck-Nielsen H., Lund H.T. A reduced number of insulin receptors in patients with Prader-Willi syndrome. Acta Endocrinol. (Copenhagen). 104:1983;345-351.
8. Dara, P. Schuster, Kwame, Osei, William, B. Zipf, Characterization of alterations in glucose and insulin metabolism in Prader-Willi subjects, Metabolism 45 (1996) 1514-1520.
9. Suter S.L., Nolan J.J., Wallage P., Gumbiner B., Olefsky J.M. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care. 15:1992;193-203.
10. John J., Nolan M.B., Bernhard L. et al. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. New Engl. J. Med. 331:1994;1188-1193.
11. Alan R.S., Jerrold M.O. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 45:1996;1661-1669.
12. Vanja A.H., Suzanne B.C., Merlin G.B. et al. Prader-Willi syndrome: consensus diagnostic criteria. Pediatrics. 91:1993;398-402.
13. Itoh M., Koeda T., Ohno K., Takeshita K. Effects of mazindol in two patients with Prader-Willi syndrome. Pediatr. Neurol. 13(4):1995;349-351.
14. Munro J.F. Clinical aspects of the treatment of obesity by drugs: a review. Int. J. Obes. 3(2):1979;171-180. (review).
15. Craddock D. Anorectic drugs: use in general practice. Drugs. 11(5):1976;378-393.
16. S. Kumar, A.J.M. Boulton, H. Beck-Nielsen, et al., Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients, Diabetologia (1996) 701-709.